Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâ...
Nemucore Medical Innovations is here to bring y...
Phoenix PharmaLabs, Inc. (PPL) is a privately held, pre-clinical stage drug develo...
Phoenix PharmaLabs, Inc. (PPL) is a privately h...
Synlogic⢠is pioneering the development of a novel class of living Synthetic Bio...
Synlogic⢠is pioneering the development of a ...
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global ...
Celgene Corporation, headquartered in Summit, N...
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developi...
Eloxx Pharmaceuticals, Inc. is a clinical-stage...
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
Join the National Investor Network and get the latest information with your interests in mind.